<DOC>
	<DOCNO>NCT01059630</DOCNO>
	<brief_summary>This open-label , multicenter , randomize Phase III study investigate efficacy , safety , pharmacokinetics pharmacoeconomics obinutuzumab ( RO5072759 , GA101 ) combine bendamustine follow continued obinutuzumab treatment ( maintenance monotherapy ) compare bendamustine alone treatment participant rituximab-refractory indolent Non-Hodgkin 's lymphoma ( iNHL ) .</brief_summary>
	<brief_title>A Study Investigate Efficacy Safety Bendamustine Compared With Bendamustine+Obinutuzumab ( GA101 ) Participants With Rituximab-Refractory , Indolent Non-Hodgkin 's Lymphoma ( GADOLIN )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>History histologically document , Blymphocyte antigen cluster differentiation 20 plus ( CD20+ ) , iNHL Refractory previous regimen contain rituximab ( defined participant respond progressed 6 month treatment rituximab rituximabcontaining regimen ) Previously treat maximum four unique chemotherapy contain treatment regimens All participant must least one bidimensionally measurable lesion ( great [ &gt; ] 1.5 centimeter ( cm ) large dimension compute tomography [ CT ] scan ) Prior use monoclonal antibody ( antiCD20 ) within 3 month prior start Cycle 1 , prior treatment obinutuzumab allow Chemotherapy investigational therapy within 28 day prior start Cycle 1 Prior treatment bendamustine ( within 2 year start Cycle 1 ) Prior allogeneic stem cell transplant History severe allergic anaphylactic reaction monoclonal antibody therapy History sensitivity mannitol Central nervous system lymphoma prior diffuse large Bcell lymphoma ( DLBCL ) , histological evidence transformation high grade diffuse large Bcell lymphoma History malignancy could affect compliance protocol interpretation result Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result Known active bacterial , viral , fungal , mycobacterial , parasitic , infection ( exclude fungal infection nail bed ) major episode infection require treatment intravenous antibiotic hospitalization within 4 week Participants history confirm progressive multifocal leukoencephalopathy ( PML ) Vaccination live vaccine minimum 28 day prior randomization Recent major surgery ( within 4 week ) , diagnosis Presence positive test result Hepatitis B surface antigen ( HBsAg ) ; antibody hepatitis B core antigen [ antiHBc ] ) detectable viral load ( positive hepatitis B virus [ HBV ] deoxyribonucleic acid [ DNA ] ) Hepatitis C Participants chronic hepatitis B seropositive occult ( HBV ) infection Participants seronegative occult HBV infection past HBV infection ( defined antiHBc positive HBV DNA negative ) could eligible willing follow accord protocol HBV DNA test Participants positive Hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction ( PCR ) negative HCV Ribonucleic acid ( RNA ) Known history human immunodeficiency virus ( HIV ) seropositive status Positive test result human Tlymphotropic virus type I ( HTLV 1 ) virus endemic country Women pregnant lactate Fertile men woman childbearing potential unless 1 ) surgically sterile 2 ) use adequate measure contraception oral contraceptive , intrauterine device , barrier method contraception conjunction spermicidal jelly Ongoing corticosteroid use &gt; 30 milligram per day ( mg/day ) prednisone equivalent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>follicular</keyword>
	<keyword>follicular lymphoma</keyword>
</DOC>